Gender, fatty liver and GGT [1]

Hepatology

Volumn 44, Issue 1, 2006, Pages 278-279

  Carulli, Lucia ^a   Lonardo, Amedeo ^a   Lombardini, Silvia ^a   Marchesini, Glulio ^b   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ESTRADIOL; ESTROGEN; GAMMA GLUTAMYLTRANSFERASE; GROWTH HORMONE; INSULIN; LEPTIN; TAMOXIFEN; THYROID HORMONE;

CARDIOVASCULAR DISEASE; DRUG USE; ECHOGRAPHY; FATTY LIVER; FERTILITY; GENERAL PRACTITIONER; GENOTYPE; HEPATITIS C VIRUS; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; LIPID STORAGE; LIVER FUNCTION; MEDICAL LITERATURE; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; PREVALENCE; SEX FACTORS;

EID: 33745887787     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21218     Document Type: Letter

References (10)

1. Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. HEPATOLOGY 2006;43:64-71.
2. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
3. Lonardo A, Carani C, Carulli N, Loria P. Endocrine NAFLD. A hormonocentric perspective of Non-Alcoholic Fatty Liver Disease pathogenesis. J Hepatol 2006;44:1196-1207.
4. Carulli L, Lombardini S, Lonardo A, Leonardi F, Bertolotti M, Ricchi M, et al. Non-alcoholic fatty liver (NAFLD). Is female sex safer? [Abstract]. J Hepatol 2004;40(Suppl):168A.
5. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 2003;37:917-923.
6. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932-937.
7. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examinadon Surveys. JAMA 1993;269:3002-3008.
8. McKenzie J, Jaap AJ, Gallacher S, Kelly A, Crawford L, Greer IA, et al. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? Clin Endocrinol (Oxf) 2003;59:682-689.
9. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005;28;333-339.
10. Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, et al. Hepatic steatosis and insulin resistance: Does etiology make a difference? J Hepatol 2006;44:190-196.